- Home
- TLSA vs NRXP Comparison
TLSA vs NRXP Comparison
Compare TLSA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 151.1M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TLSA | NRXP |
|---|---|---|
| Price | $0.90 | $2.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.08 | ★ $38.50 |
| AVG Volume (30 Days) | 518.8K | ★ 675.7K |
| Earning Date | 05-01-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,225,000.00 |
| Revenue This Year | N/A | $357.94 |
| Revenue Next Year | N/A | $1,507.30 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $1.65 |
| 52 Week High | $1.96 | $5.06 |
Technical Indicators
Market Signals| Indicator | TLSA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 41.30 |
| Support Level | $0.90 | $1.68 |
| Resistance Level | $1.17 | $3.62 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 11.76 | 57.97 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.